Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residentsArticle Published on 2022-11-012022-11-15 Journal: Influenza and Other Respiratory Viruses [Category] SARS, 진단, [키워드] age Anti-spike antibody Antibody Response BNT162b2 mRNA vaccination booster booster dose booster vaccination changed characterized COVID-19 COVID-19 outbreak Critical domain dose evaluated Factor four groups groups healthcare healthcare worker highest IgG infected individual initial lowest median mRNA nursing home residents public health RBD Responder SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose significantly higher vaccination [DOI] 10.1111/irv.13030 PMC 바로가기
The significance of surface neutrophilic MPO expression level in NETosis and NETosis-associated coagulopathies in covid-19 infected patientsResearch article Published on 2022-09-012022-10-05 Journal: Blood cells, molecules & diseases [Category] 바이오마커, 진단, [키워드] analyzed association Biomarker CLIA Coagulopathies Coagulopathy Concentration correlated correlation diagnostic value disease severity ELISA evaluate expression expression level finding flow cytometry four groups IL-6 IL-6 levels immunothrombosis infected patient Infection marker MPO myeloperoxidase NETosis NETs Neutrophil extracellular trap neutrophilic outcomes Patient plasma Prognostic factor reduced Result risk serum Serum level Surface myeloperoxidase triggering Variation were measured [DOI] 10.1016/j.bcmd.2022.102676 [Article Type] Research article
[Change in serum IgG antibody during the recovery stage of Omicron variant infection in children: an analysis of 110 cases][소아 오미크론 변이체 감염 회복기 혈청 IgG 항체 변화 : 110건 분석]Article Published on 2022-07-152022-09-11 Journal: Zhongguo dang dai er ke za zhi = Chinese journal o [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age Analysis antibody BBIBP-CorV Beijing Biological Biological products booster vaccination caused Child children China Chinese citation Clinical data Complete coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 diagnosed Diagnosis disease dose doses English four group four groups groups IgG IgG antibody inactivated Inactivated vaccine Infection journal no significant difference no significant differences Nucleic acid detection omicron pediatrics protective effect RBD IgG Recovery stage reduction in respiratory Retrospective analysis route SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 nucleic acid SARS-CoV-2 vaccination SARS-CoV-2 vaccine serum IgG Serum level severe acute respiratory syndrome Coronavirus Sex significant difference significant differences significantly higher significantly lower Sinopharm status the vaccine Tianjin Transmission two group two groups vaccination Vaccine variant was performed [DOI] 10.7499/j.issn.1008-8830.2204074 PMC 바로가기 [Article Type] Article
Advancements in Testing Strategies for COVID-19COVID-19에 대한 테스트 전략의 발전Review Published on 2022-06-132022-09-11 Journal: Biosensors [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] addition advancement Analysis approach coronavirus COVID-19 Diagnosis diagnosis of COVID-19 diagnostic disease-causing expand four groups immunoassays infect methodology outbreak pathogen platform SARS-CoV-2 SARS-CoV-2 coronavirus selective Serological testing spread of COVID-19 Strategy susceptible Testing utilization variant variants Variation virulent [DOI] 10.3390/bios12060410 PMC 바로가기 [Article Type] Review
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial6~17세 어린이 대상 ChAdOx1 nCoV-19(AZD1222) 백신의 안전성 및 면역원성: 2상 단일 맹검, 무작위, 대조 시험인 COV006의 예비 보고서Clinical Trial Published on 2022-06-112022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI administration Adults adverse event adverse events age All participants anti-SARS-CoV-2 IgG antibody Antibody titre antibody titres arbitrary unit assigned AstraZeneca AZD1222 baseline capsular Cellular responses ChAdOx1 ChAdOx1 nCoV-19 children chronic respiratory conditions Concentration Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines Cutoff Department dose doses Efficacy enrolled Fever first dose first vaccination four group four groups geometric geometric mean geometric mean ratios Geometric means group half-maximal inhibitory concentration Humoral response humoral responses immune response immune responses immunogenic immunogenicity in some intramuscular dose introduced investigators ISRCTN Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Local nucleocapsid protein Pain and tenderness participant Participants peaked Phase 2 phase 3 study preliminary report Primary outcome prime and boost raised randomised Randomly receive receiving recruitment Registered remained reported resolved respiratory response Safety safety population SARS-CoV-2 second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events seronegative seronegative participant seronegative participants seropositive serostatus single-blind stratified study drug study groups tenderness Tolerability treatment allocation Trial vaccination Vaccine Viral viral particle were recorded [DOI] 10.1016/S0140-6736(22)00770-X PMC 바로가기 [Article Type] Clinical Trial
Implementation of the ERAS (Enhanced Recovery After Surgery) protocol for hysterectomy in the Piedmont Region with an audit&feedback; approach: Study protocol for a stepped wedge cluster randomized controlled trial. A study of the EASY-NET project감사 및 피드백과 함께 Piedmont 지역의 자궁절제술을 위한 ERAS(수술 후 회복 강화) 프로토콜 구현 접근 방식: 계단형 쐐기형 클러스터 무작위 대조 시험을 위한 연구 프로토콜. EASY-NET 프로젝트 연구Article Published on 2022-05-272022-09-11 Journal: PLoS ONE [Category] 임상, [키워드] activate adopted all the patients approach approved assigned changes in Clinical outcome Clinical studies clinical study clinically Cluster Committee Compliance complications Controlled trial COVID-19 pandemic detect effect size endpoints enhanced ERAS ethical committee expected four groups healthcare hospital Hospital stay Hospitalized Hysterectomy implementation Intervention involved LOS management multicenter outcome Patient peer-reviewed Piedmont positive Primary outcome promote protocol provide Randomized controlled trial randomized trial Randomly reduce reduction Region Result Sample size Satisfaction secondary Secondary outcomes selected Statistical power stratified Stress stress response Study protocol surgery surgical Surgical stress the patient Volume women [DOI] 10.1371/journal.pone.0268655 PMC 바로가기 [Article Type] Article
COVID-19 Pandemic and Exercise (COPE) trial: a multigroup pragmatic randomised controlled trial examining effects of app-based at-home exercise programs on depressive symptomsRandomized Controlled Trial Published on 2022-05-012022-10-05 Journal: British journal of sports medicine [Category] 임상, [키워드] Analysis baseline Canadian COPE COVID-19 COVID-19 pandemic Depression depressive symptom Depressive symptoms Effect effect size exercise four groups General population global public health globe group growth implication IMPROVE intensity mental health not significantly different pandemic participant Participants populations Pragmatic promotion randomisation randomised randomised controlled trial reduce significantly Support Symptom treatment effect were measured yoga [DOI] 10.1136/bjsports-2021-104379 PMC 바로가기 [Article Type] Randomized Controlled Trial
The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells비활성화된 SARS-CoV-2 백신(CoronaVac) 및/또는 SARS-CoV-2 감염이 항체 수준, 형질모세포, 수명이 긴 형질 세포 및 자연 살해 세포에 의한 IFN-γ 방출에 미치는 영향Article Published on 2022-04-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] anti-S anti-SARS-CoV-2 spike protein anti-spike antibody antibody Antibody Response B cell CD138 CD19 CD27 Cell CoronaVac COVID-19 detectable dose Elecsy elicited ELISA kit evaluated flow cytometry four groups Germinal center group groups HCW HCWs healthcare worker Healthcare workers IAV IFN-gamma IFN-γ immunization inactivated Inactivated vaccine interferon gamma İstanbul Killer cell long-lived plasma cell long-lived plasma cells Lymph node lymph nodes median memory B cell memory B cells Migration natural infection natural killer natural killer cell no difference not differ patients percentage phenotype Plasma cells plasmablast plasmablasts qPCR RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine significantly higher significantly lower Spike protein study groups Test the antibody response the study group Turkey uninfected Vaccine Version virion was performed were measured Whole virion inactivated vaccine. [DOI] 10.1016/j.vaccine.2022.03.001 PMC 바로가기 [Article Type] Article
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months6개월 후 백신 단독 또는 SARS-CoV-2 감염 + 백신(하이브리드 면역)에 의해 유도된 항체에 의한 오미크론(B.1.1.529) 변이체의 차선 중화Article Published on 2022-04-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Against Anti-RBD IgG antibody B.1.1.529 BBV152 Biotechnology ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine correlation Covaxin Covishield cross-sectional cross-sectional study demonstrated Department exhibited explain foundation four group four groups geometric mean geometric mean titre GMT group groups hybrid Hybrid immunity Immune escape Immunity inactivated India individual Infection limit Live virus Live-virus neutralisation Melinda Gate Melinda Gates moderate natural infection nCoV neutralisation neutralisation assay neutralisation test neutralisation titre Neutralisation titres neutralise neutralising ability omicron Omicron variant outcome Primary outcome quantification Rapid reduction reduction in SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 variant serum Significant Spread subjects tested titre USA vaccinated individual vaccinated individuals vaccination Vaccine variant virus Virus neutralisation [DOI] 10.1016/j.ebiom.2022.103938 PMC 바로가기 [Article Type] Article
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination동종 ChAdOx1-nCoV-19 또는 동종 mRNA-1273 백신과 비교한 이종 ChAdOx1-nCoV-19/mRNA-1273 백신의 면역 반응 및 안전성Article Published on 2022-04-012022-09-11 Journal: Journal of the Formosan Medical Association = Taiw [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Adenovirus Adenovirus-vector vaccine Adverse adverse event adverse events AEs Alpha anti-SARS-CoV-2 IgG AstraZeneca B.1.1.7 B.1.617.2 ChAdOx1 ChAdOx1-nCoV-19 comparable coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 vaccines Efficacy enrolled event female four groups group Heterologous heterologous prime-boost homologous homologous or heterologous IgG titers immune response less median age messenger Messenger RNA vaccine Mild Moderna MOST mRNA mRNA-1273 Neutralizing antibody response Neutralizing antibody titer neutralizing antibody titers participant Primary outcome provided recruited RNA SARS-CoV-2 second dose serum Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) significantly higher Support vaccination vaccination schedule Vaccines variant Volunteer was done were recorded [DOI] 10.1016/j.jfma.2022.02.020 PMC 바로가기 [Article Type] Article